Strides Pharma Science Limited

Key metrics

Price as of 2026-07-17

Stock price

₹1074.90

Market cap

9,908 Cr

Stock P/E

14.6

P/B

3.15

Dividend yield

0.4%

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly · ₹ Cr · tap + rows to expand

Metric	Jun 2023Standalone only	Sept 2023	Dec 2023Standalone only	Mar 2024	Jun 2024Standalone only	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026
Sales	930 Cr	1,929 Cr	2,967 Cr	4,051 Cr	1,088 Cr	2,289 Cr	1,154 Cr	1,190 Cr	1,120 Cr	1,221 Cr	1,195 Cr	1,323 Cr
Operating expenses (approx.)	761 Cr	1,736 Cr	2,581 Cr	3,457 Cr	862 Cr	1,802 Cr	940 Cr	988 Cr	901 Cr	971 Cr	855 Cr	1,082 Cr
EBITDA	169 Cr	193 Cr	386 Cr	594 Cr	226 Cr	486 Cr	213 Cr	202 Cr	218 Cr	250 Cr	340 Cr	241 Cr
OPM %	18.2%	10.0%	13.0%	14.7%	20.8%	21.2%	18.5%	17.0%	19.5%	20.5%	28.4%	18.2%
Other income	9 Cr	44 Cr	53 Cr	40 Cr	13 Cr	41 Cr	6 Cr	12 Cr	9 Cr	27 Cr	107 Cr	8 Cr
Interest	76 Cr	155 Cr	234 Cr	314 Cr	80 Cr	163 Cr	52 Cr	50 Cr	47 Cr	46 Cr	43 Cr	42 Cr
Depreciation	60 Cr	120 Cr	171 Cr	221 Cr	49 Cr	99 Cr	48 Cr	49 Cr	49 Cr	50 Cr	51 Cr	53 Cr
Profit before tax	33 Cr	-81 Cr	-19 Cr	59 Cr	97 Cr	225 Cr	113 Cr	103 Cr	122 Cr	154 Cr	246 Cr	147 Cr
Tax %	29.1%	-2.7%	-63.6%	53.7%	17.4%	16.9%	21.1%	20.1%	13.5%	14.0%	15.2%	12.8%
Net profit	-9 Cr	-159 Cr	-105 Cr	-94 Cr	68 Cr	162 Cr	90 Cr	86 Cr	106 Cr	132 Cr	208 Cr	129 Cr
EPS (₹)	₹-0.79	₹-15.33	₹-9.79	₹-7.76	₹7.64	₹17.78	₹9.56	₹8.92	₹10.81	₹13.84	₹21.93	₹13.77

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2019Standalone only	Mar 2020Standalone only	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,012 Cr	2,752 Cr	3,316 Cr	3,070 Cr	3,688 Cr	4,051 Cr	4,565 Cr	4,859 Cr	Sign in for TTM
Operating expenses (approx.)	2,514 Cr	2,261 Cr	2,586 Cr	3,202 Cr	3,275 Cr	3,497 Cr	3,639 Cr	3,810 Cr	Sign in for TTM
EBITDA	498 Cr	491 Cr	730 Cr	-132 Cr	413 Cr	554 Cr	926 Cr	1,049 Cr	Sign in for TTM
OPM %	16.5%	17.9%	22.0%	-4.3%	11.2%	13.7%	20.3%	21.6%	Sign in for TTM
Other income	45 Cr	53 Cr	51 Cr	132 Cr	90 Cr	40 Cr	59 Cr	151 Cr	Sign in for TTM
Interest	205 Cr	156 Cr	150 Cr	177 Cr	261 Cr	314 Cr	249 Cr	179 Cr	Sign in for TTM
Depreciation	172 Cr	174 Cr	206 Cr	233 Cr	243 Cr	221 Cr	192 Cr	202 Cr	Sign in for TTM
Profit before tax	120 Cr	162 Cr	373 Cr	-542 Cr	-0.92 Cr	59 Cr	485 Cr	668 Cr	Sign in for TTM
Tax %	10.9%	7.0%	8.5%	32.9%	6030.6%	53.7%	16.0%	14.1%	Sign in for TTM
Net profit	330 Cr	31 Cr	258 Cr	-474 Cr	-212 Cr	-94 Cr	3,598 Cr	575 Cr	Sign in for TTM
EPS (₹)	₹36.25	₹4.06	₹29.96	₹-51.28	₹-22.49	₹-7.76	₹390.54	₹60.34	Sign in for TTM
Dividend payout %	—	—	—	—	—	—	0.6%	6.4%	Sign in for TTM

Trailing twelve months totals and margin rows

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2019Standalone only	Mar 2020Standalone only	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	90 Cr	90 Cr	90 Cr	90 Cr	90 Cr	92 Cr	92 Cr	92 Cr
Reserves	2,559 Cr	2,438 Cr	2,687 Cr	2,269 Cr	2,122 Cr	2,034 Cr	2,494 Cr	3,015 Cr
Borrowings	809 Cr	852 Cr	—	—	2,774 Cr	2,415 Cr	1,224 Cr	1,116 Cr
Other liabilities	597 Cr	648 Cr	4,238 Cr	4,617 Cr	1,691 Cr	1,354 Cr	2,238 Cr	2,662 Cr
Total liabilities	4,663 Cr	4,675 Cr	7,015 Cr	6,976 Cr	6,638 Cr	5,840 Cr	6,049 Cr	6,927 Cr
Fixed assets (net)	445 Cr	494 Cr	—	—	1,324 Cr	879 Cr	881 Cr	992 Cr
CWIP	73 Cr	86 Cr	—	—	48 Cr	80 Cr	100 Cr	161 Cr
Investments	2,149 Cr	2,171 Cr	—	—	104 Cr	113 Cr	399 Cr	279 Cr
Other assets	1,691 Cr	1,532 Cr	—	—	3,143 Cr	2,982 Cr	3,109 Cr	3,621 Cr
Total assets	4,663 Cr	4,675 Cr	7,015 Cr	6,976 Cr	6,638 Cr	5,840 Cr	6,049 Cr	6,927 Cr

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2019Standalone only	Mar 2020Standalone only	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	—	—	—	-258 Cr	44 Cr	701 Cr	684 Cr	703 Cr
Cash from investing	—	—	—	-119 Cr	302 Cr	-150 Cr	-90 Cr	-173 Cr
Cash from financing	—	—	—	421 Cr	-214 Cr	-693 Cr	-643 Cr	-453 Cr
Net cash flow	—	—	—	45 Cr	133 Cr	-142 Cr	-48 Cr	76 Cr
Free cash flow (OCF − Capex)	—	—	—	-401 Cr	-51 Cr	583 Cr	442 Cr	280 Cr

Ratios as reported or derived per annual period.

Metric	Mar 2019Standalone only	Mar 2020Standalone only	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	12.3%	12.6%	18.8%	-15.5%	3.4%	7.4%	19.3%	19.9%
ROE %	12.3%	1.4%	9.7%	-19.5%	-9.3%	-3.4%	138.9%	17.7%
Debtor days	138	144	—	—	128	103	—	—
Inventory days	191	191	—	—	289	307	315	382
Days payable	205	204	—	—	248	232	—	—
Cash conversion cycle	123	132	—	—	170	178	315	382
Debt / equity	0.25	0.27	—	—	1.28	1.17	0.47	0.35
Current ratio	1.20	1.01	—	—	1.05	1.03	1.20	1.25
Net debt / EBITDA	0.00	0.00	0.00	—	5.98	4.07	1.20	0.88

Loading peers…